Triploidy means three complete sets of chromosomes, i.e., three copies of each chromosome (3n). In humans this would total 69 chromosomes instead of the normal 46. This is a form of polyploidy, distinct from having four copies (tetraploidy), two copies (normal diploidy), or one copy (haploidy) of each chromosome. So the description of three copies of each chromosome is the correct definition.

Panorama’s standard report focuses on the chromosomal changes that cfDNA testing detects most reliably: trisomies 21, 18, and 13, together with the most common sex chromosome aneuploidies. This scope reflects what the test can consistently identify in maternal blood for a typical pregnancy. Microdeletions are not part of the standard report (they’re offered as a separate panel). Neural tube defects aren’t included because this cfDNA test isn’t designed to detect them. Also, not all trisomies are reported in the standard panel—trisomies such as 16 and 22 aren’t part of it due to limited clinical utility and interpretive challenges. Therefore, the standard Panorama report includes trisomies 21, 18, and 13 plus common sex chromosome aneuploidies.

Validation papers for diagnostic tests focus on proving how well the test performs in detecting a condition. They provide objective measurements of performance, especially sensitivity (how often the test correctly identifies true positives) and specificity (how often it correctly identifies true negatives), often along with other metrics like predictive values and confidence intervals. These papers describe study design, populations, reference standards, and thresholds so clinicians can trust the results and regulators can evaluate the test. Marketing plans, testimonials, or manufacturing process details do not assess diagnostic accuracy, so they don’t describe how well the test actually works.

Panorama Microdeletions is designed to screen for a curated set of microdeletion regions that are clinically meaningful. Instead of scanning the entire genome for any possible deletion, this option targets a predefined panel of specific loci known to be associated with recognizable syndromes. This targeted approach gives more reliable, interpretable results for those well-established regions, rather than attempting a genome-wide search which can introduce more complexity and uncertainty. The other concepts—testing the whole genome, performing no microdeletion analysis, or choosing random regions for each patient—do not describe how Panorama Microdeletions is structured.